Mise à jour d'une déclaration précédente
No de la demande: 2019-3585
Numéro de référence du titulaire d'homologation: USA-BAYERBAH-2019-US0029572 (Report 571325)
Nom du titulaire (nom légal complet, aucune abbréviation): Elanco
Adresse: 150 Research Lane, Suite 120
Ville: Guelph
État: ON
Pays: Canada
Code postal /Zip: N1G 4T2
Incident chez un animal domestique
Pays: UNITED STATES
État: MASSACHUSETTS
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 11556-155
Nom du produit: Seresto collar Large dog
Autre (préciser)
COLLAROui
Autres unités: COLLAR
Site: Animal / Usage sur un animal domestique
Professionnel de la santé
Dog / Chien
Bichon Frise crossbred
1
Homme
10
13.154
kg
Cutanée
>1 wk <=1 mo / > 1 sem < = 1 mois
>1 wk <=1 mo / > 1 sem < = 1 mois
Système
Unknown / Inconnu
Oui
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 06Jun2019, the dog had a seizure; the owner removed the collar. The dog was examined by the veterinarian and exhibited vomiting and bloody diarrhea. Bloodwork was performed and revealed an elevated phosphorus and elevated blood glucose at 573 mg/dl. The dog was started on ondansetron. On 07Jun2019, the vomiting and diarrhea resolved. On 08Jun2019, the dog had a seizure and died. The veterinarian performed an in house necropsy and the only finding was hypertrophic ventricles. The cause of death remains unknown. On 07Jun2019, the dog exhibited lethargy in the morning. Vomiting and diarrhea resolved. On 08Jun2019, the dog had a seizure, an episode of coughing, and died. The veterinarian performed an in house necropsy and the only finding was hypertrophic ventricles (cardiac disorder NOS). The cause of death remains unknown.
Mort
N - Unlikely - The product is not anticipated to cause serious neurological disorders such as seizures after appropriate topical product administration as the controlled release mechanism assures release of only low doses of active ingredient at a time. But seizures/convulsions were reported in connection with product use in dogs. However, it is known that overdose of 5 collars around the neck of adult dogs for an 8 months period and in 7 week old puppies for a 6 months period did not cause serious signs. This is supported by the extremely low systemic exposure with imidacloprid and flumethrin, particularly during the first week after application and also thereafter. Even with oral product exposure, seizures are not seen. Merely gastrointestinal signs may occur. Any action or treatment may trigger seizures in an animal with a respective disposition. Various etiologies exist for seizure events or paroxysmal signs, e.g. heart disorder, development disorder, metabolic disorder, infection, intoxication, idiopathic epilepsy, trauma, neoplasms. Reported digestive disorders are unspecific and may have numerous other causes (e.g. gastrointestinal infection, dietary incompatibility). Though mild gastrointestinal signs may occur shortly after product application, other more severe gastrointestinal signs (e.g. bloody diarrhea, hematemesis) are not typically seen with product use. No oral product exposure reported. Lethargy likely associated with other clinical signs. Reported hyperphosphatemia, hyperglycemia, coughing, cardiac disorder and later reported death are not expected after appropriate topical product application as inconsistent with product's pharmaco toxicological profile. This geriatric animal may have died due to underlying cardiac disorder. Time to onset is not suggestive of product relation. Overall, a product involvement is considered unlikely.